Enovis (NYSE:ENOV) Research Coverage Started at William Blair

William Blair assumed coverage on shares of Enovis (NYSE:ENOV) in a research report report published on Friday, MarketBeat reports. The firm issued an outperform rating on the stock.

ENOV has been the topic of several other reports. Zacks Research raised shares of Enovis from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 4th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Enovis in a research note on Friday, April 10th. Wall Street Zen raised shares of Enovis from a “hold” rating to a “buy” rating in a research note on Monday, March 30th. Needham & Company LLC raised their price objective on shares of Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Finally, Wells Fargo & Company raised shares of Enovis to a “strong-buy” rating in a research note on Wednesday, March 18th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $47.43.

Enovis Stock Up 0.0%

Shares of Enovis stock opened at $26.32 on Friday. Enovis has a one year low of $21.00 and a one year high of $37.85. The company has a debt-to-equity ratio of 0.85, a current ratio of 2.02 and a quick ratio of 1.04. The stock’s 50-day moving average is $23.39 and its 200 day moving average is $26.37. The firm has a market cap of $1.51 billion, a price-to-earnings ratio of -1.27 and a beta of 1.47.

Enovis (NYSE:ENOV) last announced its earnings results on Thursday, February 26th. The company reported $0.95 EPS for the quarter, beating the consensus estimate of $0.81 by $0.14. The company had revenue of $575.76 million for the quarter, compared to analyst estimates of $584.30 million. Enovis had a positive return on equity of 8.74% and a negative net margin of 52.69%.The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.98 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities research analysts anticipate that Enovis will post 2.79 EPS for the current year.

Insider Buying and Selling at Enovis

In other news, insider Oliver Engert purchased 1,000 shares of the company’s stock in a transaction that occurred on Friday, February 27th. The shares were bought at an average cost of $25.50 per share, with a total value of $25,500.00. Following the completion of the transaction, the insider directly owned 43,640 shares of the company’s stock, valued at approximately $1,112,820. This trade represents a 2.35% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have bought 5,000 shares of company stock worth $121,983 over the last 90 days. 2.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. River Road Asset Management LLC lifted its position in shares of Enovis by 3.2% during the fourth quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company’s stock valued at $39,621,000 after purchasing an additional 46,289 shares in the last quarter. Corient Private Wealth LLC lifted its position in shares of Enovis by 540.7% during the fourth quarter. Corient Private Wealth LLC now owns 55,180 shares of the company’s stock valued at $1,470,000 after purchasing an additional 46,568 shares in the last quarter. Front Street Capital Management Inc. lifted its position in shares of Enovis by 75.8% during the fourth quarter. Front Street Capital Management Inc. now owns 361,932 shares of the company’s stock valued at $9,642,000 after purchasing an additional 156,069 shares in the last quarter. XTX Topco Ltd bought a new stake in Enovis in the fourth quarter worth about $561,000. Finally, Susquehanna Portfolio Strategies LLC raised its position in Enovis by 249.9% in the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 140,997 shares of the company’s stock worth $3,756,000 after acquiring an additional 100,704 shares during the period. 98.45% of the stock is owned by institutional investors.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.